To counteract these effects, the expression of IL-12p70 or dominant-negative receptors for TGF-β in DCs enhances their capacity to activate cytotoxic T lymphocytes and resist tumor-mediated immunosuppression [38]. The gene discussed is TGFB1; the disease is neoplasm.